Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus Inc (EOLS) is a leading innovator in medical aesthetics, best known for Jeuveau, its FDA-approved botulinum toxin product for cosmetic lines. This page serves as the definitive source for verified Evolus news, providing investors and medical professionals with timely updates on corporate developments.
Access curated press releases and analysis covering regulatory milestones, financial results, and strategic partnerships. Our repository includes updates on aesthetic treatment innovations, market expansion efforts, and clinical research findings specific to Evolus' product pipeline.
Key coverage areas include quarterly earnings disclosures, manufacturing updates, physician adoption trends for Jeuveau, and international distribution agreements. All content is vetted for accuracy and relevance to stakeholders in the self-pay aesthetic sector.
Bookmark this page for efficient tracking of Evolus' performance in the competitive medical beauty market. Check regularly for objective reporting on operational developments and scientific advancements directly from corporate communications.
Evolus (NASDAQ: EOLS) announced the publication of a landmark independent study in JAMA Dermatology comparing four FDA-approved neurotoxins for treating glabellar lines. The double-blind study of 143 female participants aged 30-65 demonstrated Jeuveau®'s superior performance against competitors Botox®, Dysport®, and Xeomin®.
Key findings showed that Jeuveau® achieved the highest peak effect with a 93% median strain reduction at Day 30, demonstrated fast onset of action at Day 3, and maintained significant duration at Day 180, outperforming Botox® at this timepoint. The study validates Jeuveau®'s market success, which has achieved over 14% U.S. market share and penetrated more than 50% of aesthetic clinics, becoming the fastest-growing neurotoxin for four consecutive years.
Evolus (NASDAQ: EOLS), a performance beauty company focused on aesthetic consumer brands, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close.
Management will host a conference call and webcast at 4:30 p.m. ET the same day, including a Q&A session. Participants can join via phone at (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through the webcast on Evolus's Investor Relations webpage.
Evolus (NASDAQ: EOLS), a performance beauty company, has granted 12,385 restricted stock units (RSUs) to 6 newly hired non-executive employees under its 2023 Inducement Incentive Plan. The RSUs were granted on July 7, 2025, as approved by the company's compensation committee.
The RSUs will vest over a four-year period, with 25% vesting annually on each anniversary of the grant date. Continuous employment is required for vesting, and the awards are subject to the terms and conditions of both the Incentive Plan and respective RSU agreements.
Evolus (NASDAQ: EOLS) has announced its expansion into the French market through a partnership with Symatese for the distribution of Nuceiva® (botulinum toxin type A). The product is approved by the European Commission for treating moderate to severe glabellar lines in adults under 65 years.
Nuceiva®, marketed as Jeuveau® in the United States, has been the fastest-growing neurotoxin in the U.S. for four consecutive years. The product's safety and efficacy were validated through the TRANSPARENCY clinical program, which included three Phase III trials and two long-term safety studies, featuring the largest head-to-head aesthetic pivotal study versus Botox® to date.
The partnership with Symatese, a French company specializing in regenerative medical solutions, will enable direct order and delivery to French medical aesthetics healthcare professionals.
Evolus (NASDAQ: EOLS) has granted equity incentives to 16 newly hired non-executive employees in May 2025. The compensation package includes 12,706 non-qualified stock options with an exercise price of $9.98 per share and 40,576 restricted stock units (RSUs). The stock options have a 10-year term and vest over 4 years, with 25% vesting annually. Similarly, the RSUs vest 25% each year. These awards were approved under the Evolus 2023 Inducement Incentive Plan, with a grant date of May 12, 2025, and vesting commencement date of May 7, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Evolus (NASDAQ: EOLS) reported strong Q1 2025 financial results with global net revenue of $68.5 million, up 15.5% year-over-year. The company posted a GAAP operating loss of $15.2 million and a non-GAAP operating loss of $5.5 million. Despite operating in a slower market, Evolus gained meaningful market share and successfully launched Evolysse™ in Q2.
Key highlights include: over 16,000 total customers with a 70% reorder rate, Evolus Rewards™ program growing to over 1.1 million members (39% YoY increase), and record-high quarterly redemptions exceeding 220,000. The company reaffirmed its 2025 revenue guidance of $345-355 million, with Evolysse™ and Estyme® expected to contribute 8-10% of total revenue.
Looking ahead, Evolus projects reaching $700 million in revenue by 2028 (27% CAGR from 2024) and achieving non-GAAP operating income margins of at least 20% by 2028.
FAQ
What is the current stock price of Evolus (EOLS)?
What is the market cap of Evolus (EOLS)?
